IL-6 modulating drugs may reduce patients' risk of severe post-COVID-19 outcomes.<h4>Methods</h4>We conducted an emulated target trial in a retrospective cohort of patients with moderate-to-severe rheumatoid arthritis who were prescribed IL-6 receptor antagonists (sarilumab or tocilizumab, pooled treatment) or other biologic agents (anakinra or baricitinib, pooled comparator) in 2022. Here, IL6 is linked to rheumatoid arthritis.